Takeda posts strong Phase 3 win for oral psoriasis drug
Takeda said zasocitinib was generally well tolerated, with a safety profile consistent with earlier studies
Takeda said zasocitinib was generally well tolerated, with a safety profile consistent with earlier studies
The study is being conducted under a USFDA IND, has received U.S. Fast Track Designation for SLE-ITP, and has obtained IND approval from China’s Center for Drug Evaluation
Company acquires People Tree Hospital Yeshwanthpur for Rs. 430 crore
Efdoralprin alfa, a recombinant human alpha-1 antitrypsin (AAT)-Fc fusion protein, showed superior efficacy to standard plasma-derived therapy in adults with AATD
The approval for Exdensur (depemokimab-ulaa) comes on the back of SWIFT-1 and SWIFT-2 Phase III trials
The combination also outperformed chemotherapy on another important secondary endpoint
The company operates a chain of mid-sized multi-speciality hospitals
Convenient subcutaneous option has potential to reach more patients with same clinical benefits as Saphnelo IV infusion
Qfitlia is the first antithrombin (AT)-lowering therapy approved for routine prophylaxis in hemophilia
Subscribe To Our Newsletter & Stay Updated